RxSight, Inc. Stock News

ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients follow

RxSight, Inc. (RXST) Q4 2023 Earnings Call Transcript

ALISO VIEJO, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following

Steve Symington is a long-time contributor to The Motley Fool. Over the years, he's written more than 8,000 articles for the publication.

ALISO VIEJO, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,

RxSight, Inc. (NASDAQ:RXST ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Alex Huang - Director, Investor Relations Ron Kurtz - President and Chief Executive Offic

Today we look at RxSight, Inc., a small ocular focused medical device company focused on transforming the cataract surgery market. The company is delivering 70% year-over-year revenue growth and rapid

Small-cap tech stocks have been overshadowed by mega-cap tech giants despite their potential for innovation and future growth. Smaller-cap stocks have appeal for potential acquisition by larger corpor

After reaching an important support level, RxSight, Inc. (RXST) could be a good stock pick from a technical perspective. RXST surpassed resistance at the 20-day moving average, suggesting a short-term

ALISO VIEJO, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,

RxSight, Inc. (RXST) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.50 per share a year ago.

ALISO VIEJO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients followin

RxSight, Inc. (RXST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near ter

RxSight, Inc. (NASDAQ:RXST ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Alex Huang - Director, IR Ron Kurtz - President and CEO Shelley Thunen - CFO Conference Call Pa

RxSight, Inc. (RXST) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.54 per share a year ago.